Highest-materiality recent filing
CFO Eric Hyllengren departs; Marlyn Mathew named principal accounting/financial officer
CFO Eric Hyllengren separated from Zura Bio on April 20, 2026; separation not related to financial/operating results.
Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track
Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.
Zura Bio prices $125M public offering of 18.2M shares at $6.25 and 1.8M pre-funded warrants
Offering: 18.2M Class A ordinary shares at $6.25/share, plus 1.8M pre-funded warrants at $6.249 each.
Zura Bio announces CEO resignation and appointment of Sandeep Kulkarni as new CEO
Robert Lisicki resigned as CEO and director effective January 21, 2026, after medical leave since October 2025.
Zura Bio terminates prior Stone Peach/BAFFX17 agreements, issues 8.66M shares to Athanor Capital
Terminated Letter Agreements with Stone Peach and BAFFX17; entered new Athanor Agreement on Dec 29, 2025.
CEO Robert Lisicki takes medical leave; COO Kim Davis appointed interim CEO effective Oct 10
CEO Robert Lisicki informed Zura Bio of a medical leave of absence starting October 10, 2025.
Zura Bio FY 2024 net loss $45.4M ($0.60/sh); cash $176.5M, runway to 2027
Cash and cash equivalents $176.5M as of Dec 31, 2024, up from $99.8M at year-end 2023; sufficient to fund operations through 2027.
On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the “Company”) of his decision to resign from the board of directors of the Company effective as of May 21, 2026.
Max materiality 0.90 · Median 0.50 · Most common event other_material